Moderate

Resistant hypertension

Hypertension · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Blood pressure above target despite three antihypertensives (including a diuretic) at optimal/maximally tolerated doses, or BP controlled only on >=4 drugs. Must first exclude pseudo-resistance (poor technique, white-coat effect, non-adherence) and screen for secondary causes before escalating therapy.

Red flags

  • Hypertensive emergency features (chest pain, breathlessness, neuro deficit, visual loss) — separate pathway
  • Hypokalaemia (primary aldosteronism), or paroxysmal symptoms (phaeochromocytoma)
  • Rapid-onset or malignant-course hypertension, or an abdominal bruit (renovascular)
  • Deteriorating renal function on RAS blockade (bilateral renal artery stenosis)
  • Young patient with resistant HTN (secondary cause more likely)

Assessment

Differential diagnosis

  • Pseudo-resistance (inaccurate measurement, white-coat effect, non-adherence, under-dosing)
  • Primary aldosteronism (common and under-diagnosed)
  • Renal artery stenosis / renovascular disease
  • Chronic kidney disease
  • Obstructive sleep apnoea
  • Phaeochromocytoma
  • Drug/substance-induced (NSAIDs, steroids, oral contraceptive, decongestants, liquorice, alcohol, cocaine)
  • Coarctation of the aorta

Investigations

  • Confirm with ambulatory or home BP monitoring (exclude white-coat effect) and verify adherence (direct questioning, pill counts, urine/serum drug levels where available)
  • U&E, eGFR, urine ACR (renal cause), potassium (low potassium hints at aldosteronism)
  • Aldosterone:renin ratio to screen for primary aldosteronism (before adding/stopping interfering drugs where possible)
  • HbA1c, lipids, calcium; plasma/urinary metanephrines if phaeochromocytoma suspected
  • Renal artery imaging (Doppler/CT/MR angiography) if renovascular suspected
  • Screen for OSA (Epworth, sleep study); review all medications/substances raising BP
  • ECG and echo for end-organ damage (LVH)

Management

  • Exclude pseudo-resistance: confirm true resistance with out-of-office BP and address non-adherence and measurement technique
  • Reinforce lifestyle: salt restriction, weight loss, alcohol moderation, exercise; stop/substitute BP-raising drugs (NSAIDs etc.)
  • Optimise the core regimen: ACEi or ARB + calcium channel blocker + thiazide-LIKE diuretic (indapamide/chlortalidone) at proper doses
  • Screen for and treat secondary causes — especially primary aldosteronism, renovascular disease and OSA
  • Add spironolactone as the preferred 4th-line agent (PATHWAY-2) if potassium <4.5 and eGFR adequate
  • If spironolactone not tolerated/contraindicated, add a beta-blocker or alpha-blocker (doxazosin), or consider other agents
  • Refer to a hypertension specialist for truly refractory cases; consider device therapy (renal denervation) in selected patients

Drugs & doses

ACE inhibitor e.g. ramipril 5-10 mg PO once daily OR ARB e.g. losartan 50-100 mg / candesartan 8-32 mg PO once daily
Calcium channel blocker: amlodipine 5-10 mg PO once daily
Thiazide-LIKE diuretic: indapamide 2.5 mg PO once daily OR chlortalidone 12.5-25 mg PO once daily (preferred over bendroflumethiazide)
Spironolactone 25 mg PO once daily, up to 50 mg (preferred 4th-line, PATHWAY-2) — monitor potassium and renal function; avoid if eGFR <30 or K+ >4.5
Eplerenone 25-50 mg PO once daily (if gynaecomastia on spironolactone)
Doxazosin MR 4-8 mg PO once daily OR bisoprolol 5-10 mg PO once daily (alternative add-on if MRA unsuitable)
Switch loop diuretic (furosemide) for the thiazide-like agent if eGFR <30
Review and stop BP-raising drugs: NSAIDs, decongestants, systemic steroids, high alcohol/liquorice

Disposition

Manage in primary care/hypertension clinic with adherence support and secondary-cause screening; refer to a hypertension specialist for refractory or suspected secondary cases. Urgent pathway if emergency features.

Complications & pitfalls

  • Accelerated end-organ damage: LVH, heart failure, CKD progression
  • Stroke and ischaemic heart disease
  • Aortic disease
  • Retinopathy
  • Hyperkalaemia from MRA therapy

Exam pearls

  • Always exclude pseudo-resistance first — non-adherence and white-coat effect account for a large share of 'resistant' hypertension; confirm with ambulatory/home BP.
  • Primary aldosteronism is common in resistant hypertension — check the aldosterone:renin ratio; it is both a secondary cause and a predictor of spironolactone response.
  • Spironolactone is the evidence-based 4th-line drug (PATHWAY-2), outperforming doxazosin and bisoprolol — use it unless potassium is already high or eGFR too low.
  • Use a thiazide-LIKE diuretic (indapamide/chlortalidone) rather than bendroflumethiazide/hydrochlorothiazide for better BP control.
  • Renal denervation is an option in selected patients at specialist centres after optimisation.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.